Summary: After prior tirzepatide or semaglutide treatment, daily oral orforglipron preserved more of the previous weight reduction than placebo at 52 weeks. In participants who had reached a weight plateau, retained weight loss was 74.7% versus 49.2% after tirzepatide and 79.3% versus 37.6% after semaglutide. These are proportions of earlier weight loss retained, not percentages of starting body weight lost.
PICO Summary
| Element | Detail |
|---|---|
| Population | 376 participants previously treated in SURMOUNT-5: 205 from the tirzepatide cohort and 171 from the semaglutide cohort. The reported primary analysis focused on participants who had achieved a body-weight plateau before randomisation. |
| Intervention | Once-daily oral orforglipron after the preceding injectable therapy, using the trial capsule formulation titrated to 36 mg or maximum tolerated dose; follow-up to week 52. These investigational capsule doses must not be interchanged with tablet doses. Randomised active groups: 125 after tirzepatide and 105 after semaglutide. |
| Comparator | Matching oral placebo after the preceding injectable therapy: 80 participants after tirzepatide and 66 after semaglutide. From week 24, protocol-defined substantial weight regain could trigger rescue orforglipron. There was no arm continuing tirzepatide or semaglutide. |
| Outcomes | Modified treatment-regimen estimates for previous weight loss retained at week 52 among plateau participants: tirzepatide cohort, 74.7% with orforglipron versus 49.2% with placebo; difference 25.5 percentage points (95% CI 14.5 to 36.5; P<0.001). Semaglutide cohort, 79.3% versus 37.6%; difference 41.7 percentage points (95% CI 24.4 to 59.0; P<0.001). These are not new losses from original body weight. Before-rescue safety data: adverse-event discontinuations were 7.3% versus 2.5% after tirzepatide and 4.8% versus 3.0% after semaglutide. Gastrointestinal events predominated. One adjudicated pancreatitis event occurred with orforglipron in the former cohort; one cardiovascular/stroke death occurred with orforglipron in the latter. Small event counts do not establish causation or comparative long-term safety. |
| Study Design | ATTAIN-MAINTAIN: double-blind, placebo-controlled, randomised phase 3b, 52-week maintenance trial with separate prior-treatment cohorts. Plateau was defined as less than 5% body-weight change during weeks 60-72 of SURMOUNT-5. The modified treatment-regimen analysis imputed post-rescue values without assuming additional benefit from rescue. Funded by Eli Lilly. ClinicalTrials.gov NCT06584916. Distinct from SURMOUNT-5 itself. |
Expert Commentary
I see this as useful evidence for a maintenance strategy, provided the comparator and denominator remain explicit. Orforglipron preserved more of the weight reduction already achieved than placebo, but neither cohort retained all of that reduction on average. The percentages are easily misunderstood: retaining roughly three quarters of previous weight loss is not losing three quarters of baseline body weight. The main limitation is the absence of a continued-injection comparator. The trial therefore cannot show that switching is as effective as staying on tirzepatide or semaglutide, nor that an oral option is the best next step for every patient. Selection from an earlier trial and the plateau-focused primary analysis also narrow generalisability. Gastrointestinal tolerability and Lilly sponsorship should remain visible alongside the efficacy message. Can I use this with my patients? It can inform a specialist discussion about maintenance after injectable therapy where treatment is locally authorised and appropriate, particularly when route of administration matters. It should not prompt an unsupervised switch or be presented as evidence that obesity treatment can simply stop. I would want direct comparisons with continued injectable therapy, longer follow-up and patient-centred adherence data before claiming equivalent long-term benefit or lower overall treatment burden in routine clinical practice.
References
Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687. doi:10.1038/s41591-026-04386-7. PMID: 42120723.
